(Q52943519)

9 May 2018

title

Combined therapy in children and adolescents with classical Hodgkin's lymphoma: A report from the SFCE on MDH-03 national guidelines. (English)

1 reference

9 May 2018

author

Jacqueline Clavel

27

1 reference

9 May 2018

author name string

E Seror

1

1 reference

9 May 2018

J Donadieu

2

1 reference

9 May 2018

H Pacquement

3

1 reference

9 May 2018

S Abbou

4

1 reference

9 May 2018

A Lambilliotte

5

1 reference

9 May 2018

M Schell

6

1 reference

9 May 2018

C Curtillet

7

1 reference

9 May 2018

V Gandemer

8

1 reference

9 May 2018

M Pasquet

9

1 reference

9 May 2018

N Aladjidi

10

1 reference

9 May 2018

P Lutz

11

1 reference

9 May 2018

C Schmitt

12

1 reference

9 May 2018

A Deville

13

1 reference

9 May 2018

O Minckes

14

1 reference

9 May 2018

J P Vanier

15

1 reference

9 May 2018

C Armari-Alla

16

1 reference

9 May 2018

C Thomas

17

1 reference

9 May 2018

S Gorde-Grosjean

18

1 reference

9 May 2018

F Millot

19

1 reference

9 May 2018

P Blouin

20

1 reference

9 May 2018

N Garnier

21

1 reference

9 May 2018

C Coze

22

1 reference

9 May 2018

C Devoldere

23

1 reference

9 May 2018

Y Reguerre

24

1 reference

9 May 2018

S Helfre

25

1 reference

9 May 2018

L Claude

26

1 reference

9 May 2018

O Oberlin

28

1 reference

9 May 2018

J Landman-Parker

29

1 reference

9 May 2018

T Leblanc

30

1 reference

9 May 2018

publication date

1 October 2016

1 reference

9 May 2018

Pediatric Hematology and Oncology

published in

1 reference

9 May 2018

volume

33

1 reference

9 May 2018

issue

7-8

1 reference

9 May 2018

page(s)

423-437

1 reference

9 May 2018

The effects of etoposide on testicular function in boys treated for Hodgkin's disease

cites work

1 reference

https://api.crossref.org/works/10.1080%2F08880018.2016.1247393

Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08880018.2016.1247393

Hodgkin lymphoma in children and adolescents: improving the therapeutic index

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08880018.2016.1247393

Localized childhood Hodgkin's disease: response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy-results of the French Society of Pediatric Oncology Study MDH90

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08880018.2016.1247393

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08880018.2016.1247393

The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08880018.2016.1247393

Outcome of children and adolescents with recurrent/refractory classical Hodgkin lymphoma, a study from the Société Française de Lutte contre le Cancer des Enfants et des Adolescents (SFCE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08880018.2016.1247393

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08880018.2016.1247393

A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08880018.2016.1247393

Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08880018.2016.1247393

Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08880018.2016.1247393

The prognostic value of biological markers in paediatric Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08880018.2016.1247393

MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08880018.2016.1247393

Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08880018.2016.1247393

Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08880018.2016.1247393

Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08880018.2016.1247393

Breast cancer and other second neoplasms after childhood Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08880018.2016.1247393

Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08880018.2016.1247393

Breast cancer after chest radiation therapy for childhood cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08880018.2016.1247393

Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08880018.2016.1247393

Management of children with high-risk Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08880018.2016.1247393

Incidence of childhood cancer in France: National Children Cancer Registries, 2000–2004

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08880018.2016.1247393

10.1080/08880018.2016.1247393

21 January 2018

Identifiers

DOI

1 reference

9 May 2018

PubMed ID

27960645

1 reference

9 May 2018